Logo image of MNOV

MEDICINOVA INC (MNOV) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MNOV - US58468P2065 - Common Stock

1.42 USD
+0.02 (+1.43%)
Last: 1/8/2026, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MNOV. MNOV was compared to 530 industry peers in the Biotechnology industry. MNOV has a great financial health rating, but its profitability evaluates not so good. MNOV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MNOV had negative earnings in the past year.
MNOV had a negative operating cash flow in the past year.
In the past 5 years MNOV always reported negative net income.
MNOV had a negative operating cash flow in each of the past 5 years.
MNOV Yearly Net Income VS EBIT VS OCF VS FCFMNOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of MNOV (-23.22%) is better than 73.21% of its industry peers.
The Return On Equity of MNOV (-25.13%) is better than 79.81% of its industry peers.
Industry RankSector Rank
ROA -23.22%
ROE -25.13%
ROIC N/A
ROA(3y)-17.22%
ROA(5y)-16.33%
ROE(3y)-18.28%
ROE(5y)-17.27%
ROIC(3y)N/A
ROIC(5y)N/A
MNOV Yearly ROA, ROE, ROICMNOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30

1.3 Margins

MNOV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNOV Yearly Profit, Operating, Gross MarginsMNOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

MNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
MNOV has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for MNOV has been increased compared to 5 years ago.
There is no outstanding debt for MNOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MNOV Yearly Shares OutstandingMNOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MNOV Yearly Total Debt VS Total AssetsMNOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

MNOV has an Altman-Z score of -1.56. This is a bad value and indicates that MNOV is not financially healthy and even has some risk of bankruptcy.
MNOV's Altman-Z score of -1.56 is in line compared to the rest of the industry. MNOV outperforms 52.83% of its industry peers.
There is no outstanding debt for MNOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.56
ROIC/WACCN/A
WACC8.83%
MNOV Yearly LT Debt VS Equity VS FCFMNOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 9.86 indicates that MNOV has no problem at all paying its short term obligations.
MNOV's Current ratio of 9.86 is amongst the best of the industry. MNOV outperforms 80.38% of its industry peers.
A Quick Ratio of 9.86 indicates that MNOV has no problem at all paying its short term obligations.
MNOV has a better Quick ratio (9.86) than 80.94% of its industry peers.
Industry RankSector Rank
Current Ratio 9.86
Quick Ratio 9.86
MNOV Yearly Current Assets VS Current LiabilitesMNOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MNOV have decreased strongly by -19.05% in the last year.
The Revenue for MNOV has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.64% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-77.39%
EPS Next 2Y-25.47%
EPS Next 3Y-21.05%
EPS Next 5Y11.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNOV Yearly Revenue VS EstimatesMNOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2029 2030 2031 2032 200M 400M 600M 800M
MNOV Yearly EPS VS EstimatesMNOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MNOV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNOV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNOV Price Earnings VS Forward Price EarningsMNOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNOV Per share dataMNOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

A cheap valuation may be justified as MNOV's earnings are expected to decrease with -21.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.47%
EPS Next 3Y-21.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MNOV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MEDICINOVA INC

NASDAQ:MNOV (1/8/2026, 8:00:01 PM)

1.42

+0.02 (+1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)02-17 2026-02-17/amc
Inst Owners21.76%
Inst Owner Change0%
Ins Owners2.88%
Ins Owner Change0%
Market Cap69.65M
Revenue(TTM)N/A
Net Income(TTM)-11.05M
Analysts82.5
Price Target7.14 (402.82%)
Short Float %0.59%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.47%
Min EPS beat(2)27.76%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)29.99%
Min EPS beat(4)-6.95%
Max EPS beat(4)57.98%
EPS beat(8)6
Avg EPS beat(8)21.7%
EPS beat(12)10
Avg EPS beat(12)25.84%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.58
P/tB 2.36
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS0.9
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.22%
ROE -25.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.22%
ROA(5y)-16.33%
ROE(3y)-18.28%
ROE(5y)-17.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.01%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.86
Quick Ratio 9.86
Altman-Z -1.56
F-Score2
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)53.06%
Cap/Depr(5y)91.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-77.39%
EPS Next 2Y-25.47%
EPS Next 3Y-21.05%
EPS Next 5Y11.64%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.11%
OCF growth 3YN/A
OCF growth 5YN/A

MEDICINOVA INC / MNOV FAQ

What is the ChartMill fundamental rating of MEDICINOVA INC (MNOV) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MNOV.


What is the valuation status of MEDICINOVA INC (MNOV) stock?

ChartMill assigns a valuation rating of 0 / 10 to MEDICINOVA INC (MNOV). This can be considered as Overvalued.


Can you provide the profitability details for MEDICINOVA INC?

MEDICINOVA INC (MNOV) has a profitability rating of 1 / 10.


How financially healthy is MEDICINOVA INC?

The financial health rating of MEDICINOVA INC (MNOV) is 7 / 10.


What is the earnings growth outlook for MEDICINOVA INC?

The Earnings per Share (EPS) of MEDICINOVA INC (MNOV) is expected to decline by -77.39% in the next year.